Call Today

(March 12, 2026) Webinar: Preclinical Imaging of Multiple Myeloma Bone Disease by Dual-Energy X-ray Absorptiometry (DXA)

(March 12, 2026) Webinar: Preclinical Imaging of Multiple Myeloma Bone Disease by Dual-Energy X-ray Absorptiometry (DXA)

Register

Overview:

Multiple Myeloma (MM) is a plasma cell malignancy originating in the bone marrow and is frequently accompanied by severe skeletal complications. Over 80% of MM patients develop osteolytic bone disease, resulting in fractures, pain, and reduced quality of life. Consequently, MM treatment strategies combine anti-cancer therapies with bone-modifying agents designed to limit cancer-induced bone loss.

This webinar provides an overview of MM and the mechanisms driving MM-associated bone disease, emphasizing the importance of accurate, longitudinal bone assessment in preclinical research. Attendees will be introduced to case examples and published data from MM animal models, with a focus on how dual-energy X-ray absorptiometry (DXA) has been used to quantify bone mineral density (BMD) and evaluate therapeutic response.

In addition, the session will highlight how DXA could have been further leveraged in these studies to extract additional, clinically relevant insights through whole-body and regional measurements over time. The webinar will conclude with a comparison of MM animal models and patient disease, discussing how closely preclinical findings reflect clinical bone pathology and how systems like iNSiGHT DXA help strengthen translational relevance.

Key Learning Objectives:

  • Understand Multiple Myeloma and its impact on bone health: Describe the pathophysiology of MM-associated bone disease and why skeletal assessment is critical for evaluating disease progression and therapeutic response.
  • Learn how DXA is applied in MM animal models: Understand how DXA is used in published preclinical studies to quantify bone loss, monitor longitudinal changes, and assess the effects of anti-cancer and bone-modifying therapies.
  • Evaluate the translational value of MM animal models using DXA data: Compare bone disease in MM animal models versus patients and assess how DXA measurements help bridge preclinical findings to clinical relevance.

 

Date

Mar 12 2026
10:00 am - 11:00 am

Speaker

  • Tiina Kähkönen
    Tiina Kähkönen Research Director & Chief Scientific Officer at Oncobone
    Tiina Kähkönen
    Tiina Kähkönen
    Research Director & Chief Scientific Officer at Oncobone

    Tiina Kähkönen graduated from University of Turku, Finland, and received her MSc degree from Pharmacology and Drug development program in 2012. After that she did her PhD concentrating on breast cancer metastasis and drug treatment and defended her thesis in 2019. After that she moved to industry and has worked in several positions involving preclinical oncology drug development as a Research Director and as a Chief Scientific Officer.

    During her career, Tiina has conducted or supervised many studies involving small laboratory animals. Main indications in these studies have been oncology and bone diseases. Applicable technologies that Tiina has used during her career include bioluminescence and fluorescence -based tumor imaging, DXA, pQCT and µCT for bone imaging, and different behavioural tests and body composition analyses. This experience has been very important for her to advice her clients and partners in utilizing most suitable imaging technologies for their research.

Register

Explore our Past Webinars